Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 067: Nivolumab +/- Ipilimumab vs Ipilimumab in Melanoma
NCT01844505Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2013
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of nivolumab in melanoma (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-Free Survival at 20 months and Overall Survival at 39 months. Started Jun 2013; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01844505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01844505.